Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

PHASE2CompletedINTERVENTIONAL
Enrollment

483

Participants

Timeline

Start Date

August 6, 2013

Primary Completion Date

September 25, 2014

Study Completion Date

November 12, 2019

Conditions
Migraine
Interventions
DRUG

Erenumab

Administered by study site staff once a month (QM) as a subcutaneous injection

DRUG

Placebo

Administered by study site staff once a month (QM) as a subcutaneous injection

DRUG

Erenumab PFS

Erenumab supplied in a single-use prefilled syringe for self-administration in the CHU substudy

DRUG

Erenumab AI/Pen

Erenumab supplied in a single-use autoinjector/pen for self-administration in the CHU substudy

Trial Locations (66)

1337

Research Site, Sandvika

2317

Research Site, Hamar

2600

Research Site, Glostrup Municipality

4005

Research Site, Stavanger

6003

Research Site, Ålesund

8000

Research Site, Aarhus C

10117

Research Site, Berlin

10409

Research Site, Berlin

10435

Research Site, Berlin

14609

Research Site, Rochester

19107

Research Site, Philadelphia

20100

Research Site, Turku

20246

Research Site, Hamburg

22042

Research Site, Falls Church

23454

Research Site, Virginia Beach

27405

Research Site, Greensboro

27612

Research Site, Raleigh

30033

Research Site, Decatur

32935

Research Site, Melbourne

33100

Research Site, Tampere

33407

Research Site, West Palm Beach

33410

Research Site, Palm Beach Gardens

34205

Research Site, Bradenton

37203

Research Site, Nashville

40213

Research Site, Louisville

40513

Research Site, Lexington

44789

Research Site, Bochum

45133

Research Site, Essen

48034

Research Site, Southfield

48104

Research Site, Ann Arbor

49009

Research Site, Kalamazoo

50100

Research Site, Mikkeli

55441

Research Site, Plymouth

63141

Research Site, St Louis

65807

Research Site, Springfield

67207

Research Site, Wichita

75214

Research Site, Dallas

75231

Research Site, Dallas

76017

Research Site, Arlington

77074

Research Site, Houston

78731

Research Site, Austin

84106

Research Site, Salt Lake City

84124

Research Site, Salt Lake City

85032

Research Site, Phoenix

90220

Research Site, Oulu

90404

Research Site, Santa Monica

90806

Research Site, Long Beach

91403

Research Site, Sherman Oaks

91950

Research Site, National City

91978

Research Site, Spring Valley

92663

Research Site, Newport Beach

94109

Research Site, San Francisco

06810

Research Site, Danbury

06824

Research Site, Fairfield

06905

Research Site, Stamford

02472

Research Site, Watertown

01605

Research Site, Worcester

M4S 1Y2

Research Site, Toronto

H2L 4M1

Research Site, Montreal

00100

Research Site, Helsinki

04107

Research Site, Leipzig

521 37

Research Site, Falköping

222 22

Research Site, Lund

112 45

Research Site, Stockholm

114 33

Research Site, Stockholm

162 68

Research Site, Vällingby

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01952574 - Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention | Biotech Hunter | Biotech Hunter